Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Henry is active.

Publication


Featured researches published by Michael Henry.


Free Radical Biology and Medicine | 1999

Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis.

Irfan Rahman; Elzbieta Skwarska; Michael Henry; Margaret Davis; Clare O’Connor; M. X. FitzGerald; A P Greening; William MacNee

An oxidant/antioxidant imbalance has been proposed in patients with idiopathic pulmonary fibrosis (IPF). We tested this hypothesis by measuring various parameters of the oxidant/antioxidant balance in the plasma of 12 patients with IPF (7 nonsmokers and 5 smokers); in the bronchoalveolar lavage fluid (BALF) of 24 patients with IPF (17 nonsmokers and 7 smokers) and 31 healthy subjects (23 nonsmokers and 8 smokers). The trolox equivalent antioxidant capacity (TEAC) in plasma and BALF was lower in nonsmoking patients with IPF (plasma 0.55+/-0.1 mM, p<.001; BALF 4.8+/-1.2 microM, mean +/-SEM, p<.01), compared with healthy nonsmokers (plasma 1.33+/-0.03 mM; BALF 10+/-2 microM). Similar trends in plasma and BALF TEAC were observed in smoking patients with IPF in comparison with healthy smokers. The decrease in BALF TEAC was concomitant with a decrease in BALF protein thiol levels, but the decrease TEAC levels in plasma in IPF patients was not accompanied by a decrease in protein thiol levels. Reduced glutathione (GSH) was lower in BALF in nonsmoking patients with IPF (1.0+/-0.1 microM) compared with healthy nonsmokers (2.3+/-0.2 microM, p<.001). In contrast, GSH levels were higher in smoking patients with IPF (5.2+/-1.1 microM, p<.001) than in nonsmoking patients. GSSG levels were not different in any of the groups. The levels of products of lipid peroxidation measured as thiobarbituric acid reactive substances (TBARS) in plasma and BALF were significantly increased in both smoking (plasma 2.2+/-0.5 microM, p<.01; BALF 0.18+/-0.04 microM, p<.001), and nonsmoking (plasma 2.1+/-0.3 microM, p<.01; BALF 0.22+/-0.05 microM, p<.001) IPF patients, compared with healthy nonsmokers (plasma 1.4+/-0.3 microM; BALF 0.05+/-0.004 microM). These data show evidence of oxidant/antioxidant imbalance in the lungs of patients with IPF, which is also reflected as systemic oxidant stress.


Thorax | 2000

Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease

Irfan Rahman; Elzbieta Swarska; Michael Henry; Jan Stolk; William MacNee

BACKGROUND It has been suggested that oxidative stress is an important factor in the pathogenesis of chronic obstructive pulmonary disease (COPD). We have shown that an oxidant/antioxidant imbalance occurs in the distal air spaces of smokers and in patients with COPD which is reflected systemically in the plasma. A study was undertaken to determine whether plasma antioxidant status correlated with lung function as assessed by forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) in smokers and patients with COPD. METHODS Plasma antioxidant capacity, assessed by the Trolox equivalent antioxidant capacity (TEAC) as an index of overall systemic oxidative stress, and protein thiol levels were measured in 95 patients with stable COPD, in 82 healthy smokers, and in 37 healthy non-smokers. RESULTS Mean (SE) plasma TEAC levels were significantly decreased in patients with COPD (0.81 (0.03)u2009mmol/l, p<0.001) and in healthy smokers (0.87 (0.04)u2009mmol/l, p<0.001) compared with healthy non-smokers (1.31 (0.11)u2009mmol/l). The mean differences in plasma antioxidant capacity (mM) were (0.81, 95% confidence interval (CI) 0.22 to 1.48), (0.87, 95% CI 0.2 to 1.46), and (1.31, 95% CI 1.09 to 1.58) in patients with COPD, healthy smokers, and healthy non-smokers, respectively. This reduction was associated with a 29% (95% CI 18 to 38) and a 30% (95% CI 19 to 40) decrease in plasma protein thiol levels in COPD patients and smokers, respectively. Current smoking was not the main contributor to the reduction in antioxidant capacity in patients with COPD as those patients who were still smokers had similar TEAC levels (mean (SE) 0.78 (0.05); n = 25) to those who had stopped smoking (0.84 (0.02); n = 70). No significant correlations were found between spirometric data measured as FEV1 % predicted or FEV1/FVC % predicted and the plasma levels of TEAC in patients with COPD, healthy smokers, or healthy non-smokers. Similarly, there was no significant correlation between FEV1 % predicted or FEV1/FVC % predicted and the levels of plasma protein thiols in the three groups. CONCLUSIONS These data confirm decreased antioxidant capacity in smokers and patients with COPD, indicating the presence of systemic oxidative stress. However, no relationship was found between protein thiols or TEAC levels and measurements of airflow limitation in either smokers or in patients with COPD.


Chest | 2016

A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis.

Ilaria Campo; Maurizio Luisetti; Matthias Griese; Bruce C. Trapnell; Francesco Bonella; Jan C. Grutters; Koh Nakata; Coline H.M. van Moorsel; Ulrich Costabel; Vincent Cottin; Toshio Ichiwata; Yoshikazu Inoue; Antonio Braschi; Giacomo Bonizzoni; Giorgio Antonio Iotti; Carmine Tinelli; Giuseppe Rodi; Toru Arai; Andrey Bazhanov; Issahar Ben-Dov; Alicia Casey; Deniz Dogru; Wolfgang Gesierich; Maija Halme; Michael Henry; Felix J.F. Herth; Wang Hui-ying; Julia Ilkovich; Sarosh Irani; Vítězslav Kolek

AFFILIATIONS: From the Department of Pulmonary and Critical Care Medicine, Northwestern University. FINANCIAL/NONFINANCIAL DISCLOSURES: See earlier cited article for author conflicts of interest. CORRESPONDENCE TO: Sean B. Smith, MD, Pulmonary and Critical Care Medicine, Feinberg School of Medicine, Northwestern University, 660 N Westmoreland Rd, Lake Forest, IL 60045; e-mail: [email protected] Copyright 2016 Published by Elsevier Inc under license from the American College of Chest Physicians. DOI: http://dx.doi.org/10.1016/j.chest.2016.04.023]


Chest | 2000

A Polymorphism in the Tumor Necrosis Factor-α Gene Promoter Region May Predispose to a Poor Prognosis in COPD

Vera M. Keatings; Samantha J. Cave; Michael Henry; Kevin Morgan; Clare O'Connor; M. X. FitzGerald; Noor Kalsheker


American Journal of Respiratory and Critical Care Medicine | 1998

Neutrophil adhesion molecule surface expression and responsiveness in cystic fibrosis

Kenneth J. Russell; James P. McRedmond; Nina Mukherji; Christine M. Costello; Vera M. Keatings; Seamus Linnane; Michael Henry; M. X. FitzGerald; Clare O'Connor


Gastrointestinal Endoscopy | 2018

Su1371 PROSPECTIVE EVALUATION OF CLINICAL, LABORATORY, AND TUMOR-RELATED CHARACTERISTICS ASSOCIATED WITH HEMATOGENOUS TUMOR SEEDING FOLLOWING EUS FNA OF PANCREATIC DUCTAL ADENOCARCINOMA

Michael J. Levy; Benjamin R. Kipp; Dragana Milosevic; Amber Schneider; Jesse S. Voss; Rajeswari Avula; Sarah E. Kerr; Michael Henry; W. Edward Highsmith; Minetta C. Liu; Ferga C. Gleeson


Gastroenterology | 2018

Sa1981 - Prospective Cell Free DNA Assessment of the Risk of Tumor Seeding Following Primary Tumor EUS FNA with Concomitant Peripheral Blood, Portal Vein, and Hepatic Vein FNA Assessment

Michael J. Levy; Benjamin R. Kipp; Dragana Milosevic; Amber Schneider; Jesse S. Voss; Rajeswari Avula; Sarah E. Kerr; Michael Henry; W. Edward Highsmith; Minetta C. Liu; Ferga C. Gleeson


Gastroenterology | 2018

Su1318 - Prospective Molecular Assessment of Kras Mutation Concordance Rate Between Peripheral Blood and Primary Tumor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing EUS FNA

Michael J. Levy; Benjamin R. Kipp; Dragana Milosevic; Amber Schneider; Jesse S. Voss; Rajeswari Avula; Sarah E. Kerr; Michael Henry; W. Edward Highsmith; Minetta C. Liu; Ferga C. Gleeson


Gastroenterology | 2016

Sa1521 SMAD4 Biomarker Stratification Strategy via Endoscopic Ultrasound Fine Needle Aspiration Using Targeted Next-Generation Sequencing for Patients With Pancreatic and Ampullary Adenocarcinoma

Ferga C. Gleeson; Benjamin R. Kipp; Jesse S. Voss; Douglas M. Minot; ZhengJin Tu; Sarah E. Kerr; Michael Henry; George Vasmatzis; John C. Cheville; Konstantinos N. Lazaridis; Michael J. Levy


Gastroenterology | 2016

Sa1455 KRAS Mutant Subtype Assessment of Pancreatic and Ampullary Adenocarcinoma by EUS FNA Molecular Cytology Targeted Next Generation Sequencing

Ferga C. Gleeson; Benjamin R. Kipp; Jesse S. Voss; Douglas M. Minot; ZhengJin Tu; Sarah E. Kerr; Michael Henry; George Vasmatzis; John C. Cheville; Konstantinos N. Lazaridis; Michael J. Levy

Collaboration


Dive into the Michael Henry's collaboration.

Researchain Logo
Decentralizing Knowledge